Von Hippel-Lindau Disease
22
10
11
7
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 22 trials
100.0%
+13.5% vs benchmark
5%
1 trials in Phase 3/4
29%
2 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (22)
Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
Familial Investigations of Childhood Cancer Predisposition
Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors
Retrospective Case Series of Trans-scleral Cryotherapy for Retinal Hemangioblastoma
Institutional Registry of Rare Diseases
Precision Medicine for Neurocutaneous Syndromes in Western China
Promoting Stress Management and Resilience Among Individuals With Von Hippel- Lindau Disease
MK-3795 (PT2385) for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma (MK-3795-003)
Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients
Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau Disease
MyVHL: Patient Natural History Study
Mechanisms of Somatic Mutation and Tumor Initiation in Pre-malignant Kidney Tubule Cells
Propranolol and Von Hippel-Lindau Disease
68Ga-NY104 PET/CT in Von Hippel-Lindau Disease
A Study of BPI-452080 in Subjects With Solid Tumors
Drivers of Hypoxia-induced Angiogenesis in Tumor Development
Natural History and Management of Pancreatic Lesions in Von Hippel-Lindau Disease
Effect of Vorinostat on Nervous System Hemangioblastomas in Von Hippel-Lindau Disease (Missense Mutation Only)
Screening for Endolymphatic Sac Tumours (ELSTs) in Von Hippel-Lindau (vHL) Patients